¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Target of perceived adverse discrimination and persecution"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® adverse effect ÇÑ±Û ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
¼³¸í   
  ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§ ³ªÅ¸³ª´Â Ä¡·á¸ñÀû¿¡ ºÎÇÕµÇÁö ¾Ê´Â ºÒÄèÇÑ ÀÛ¿ë, Áï ºÎÀÛ¿ëÀ» ¿ªÈ¿°ú·Î Ç¥ÇöÇϴ °æ¿ì°¡ ÀÖ´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­´Â ¿ªÈ¿°ú¶õ ¡°¿¹¹æ, Áø´Ü, Ä¡·áÀÇ ¸ñÀûÀ¸·Î »ç¶÷¿¡°Ô »ó¿ë·®ÀÇ ¾àÀ» »ç¿ëÇÏ¿´À» ¶§ ¹ßÇöÇϴ Àå¾Ö·Î, ÀǵµÇÏÁö ¾ÊÀº Àۿ롱À̶ó°í Á¤ÀÇÇϰí ÀÖ´Ù. ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§, Æ¯È÷ ÁÖ¸ñÇÏ¿©¾ß ÇÒ ÀϹÝÀûÀΠ¿ªÈ¿°ú·Î¼­ ¾à¹°¾Ë·¹¸£±â, Á¶Ç÷Àå±â Àå¾Ö, °£-ÄáÆÏÀÇ Àå¾Ö, ¹°Áú ´ë»ç Àå¾Ö µîÀÌ ÀÖ´Ù. ÀÌ ¿Ü¿¡ ÀÓ»êºÎ¿¡°Ô Åõ¿©ÇÏ¿© ¹ß»ýÇÑ ±âÇü¹ß»ý, ¸¶¾à, °¢¼ºÁ¦, ±âŸ ÇâÁ¤½ÅÁ¦¿¡ ÀÇÇÑ ÀÇÁ¸¼º Çü¼ºµµ Áß¿äÇÏ´Ù.
  
  
¿µ¹® Dilatation and Curettage(D & C) ÇÑ±Û Àڱñܾ¼ú, ÀڱøñÈ®Àå
¼³¸í   
  ÀÚ±ÃÀ̶õ Å¾ư¡ ¼öŵǾ ºÐ¸¸Àü±îÁö ¹ßÀ°ÇÏ°í ¼ºÀåÇϴ °ø°£ÀÌ´Ù. Àڱüӿ¡ º´º¯ÀÌ ÀÖ¾î ÀÓ½ÅÀÌ °è¼ÓµÉ ¼ö ¾ø°Å³ª ¾Æ´Ï¸é ´Ù¸¥ ÀÌÀ¯·Î ÀӽŵǾî Àִ Å¾Ƹ¦ Á¦°ÅÇϰíÀÚ ÇÒ °æ¿ì¿¡ »ç¿ëµÇ´Â ¹æ¹ýÀÌ´Ù. ¿©±â¼­ ±Ü¾î³»±â À§ÇÏ¿©´Â ¿ì¼± ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇϴ ÀڱøñÀ» È®Àå½ÃÄѾߠÇÑ´Ù. ¿©±â¿¡´Â ±Þ¼ÓÈ÷ È®ÀåÀ» ½ÃµµÇϴ ¹ý°ú ¼­¼­È÷ È®ÀåÀ» ½ÃµµÇϴ 2°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ÀڱøñÀ» ±Þ¼ÓÈ÷ È®ÀåÇÒ ¶§´Â Çì°¡¸£ ¸ñ°üÈ®Àå±â(Hegar's dilatator)¸¦ »ç¿ëÇÑ´Ù. À̰ÍÀº ÀÛÀº ±Ý¼Ó¸·´ë·Î ÀÛÀº Å©±âºÎÅÍ Å« Å©±â±îÁö ´Ù¾çÇÑ Å©±â°¡ À־ ¿ì¼± ÀÛÀº ¸·´ë·Î ½ÃÀÛÇÏ¿© Á¡Á¡ Å« Å©±âÀÇ ¸·´ë¸¦ Àڱøñ¿¡ ³Ö¾î¼­ ÀڱøñÀ» È®Àå½ÃŲ´Ù. ¼­¼­È÷ È®Àå½Ãų ¶§´Â Laminaria tent¸¦ ¸ñ°ü¿¡ »ðÀÔÇϴ ¹æ¹ýÀ» »ç¿ëÇÑ´Ù. Laminaria tent¶õ ÇØÃʷΠ¸¸µç ÀÛÀº ¸·´ë·Î ¼öºÐÀ» Èí¼öÇϸé Á¡Á¡ ´Ã¾î³ª´Â ¼ºÁúÀÌ ÀÖ´Ù. À̰ÍÀ» ÀÚ±ÃÀÇ ¸ñ¿¡ ³ÖÀ¸¸é À̰ÍÀÌ ¼öºÐÀ» Èí¼öÇÏ¿© ´Ã¾î³ª¹Ç·Î ÃµÃµÈ÷ ÀÚ±ÃÀÇ ¸ñÀÌ ´Ã¾î³­´Ù. ÀڱøñÀÌ ÃæºÐÈ÷ ´Ã¾î³ª¸é ±× ¼ÓÀ¸·Î ³¡ÀÌ ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ ³Ö¾î¼­ ÀڱüÓÀÇ º´º¯À̳ª ÀӽŵȠžƸ¦ ±Ü¾î³»´Âµ¥ ¿©±â¿¡ »ç¿ëµÇ´Â ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ Å¥·¿À̶ó°í ÇÑ´Ù. Ãʱâ ÀÓ½ÅÁßÀý Áï À¯»ê°ú °°Àº ÀӽŰú °ü·ÃµÈ °æ¿ì»Ó¸¸ ¾Æ´Ï¶ó, ºñÀӽŠÀÚ±ÃÀÇ Àڱ󻸷Á¶Á÷ÀǠäÃë ¹× Á¦°Å¸¦ À§Çؼ­µµ ÇàÇØÁö´Â ¼ö±âÀÌ´Ù. À̴ ¿øÄ¢ÀûÀ¸·Î ¸¶ÃëÇÏ¿¡ ½Ç½ÃµÇ´Â °ÍÀ¸·Î Àڱøñ°üÀ» È®ÀåÇÏ°í ±â±¸·Î Àڱà³»¿ë¹°À» Á¦°ÅÇϰí Å¥·¿À¸·Î Àڱ󻺮À» ±ú²ýÀÌ ÇÑ´Ù. ÀÚ±Ãõ°øÀ̳ª ÀڱøñÀÇ ÆÄ¿­ µîÀÇ À§ÇèÀÌ µû¸£¸ç, ¼ö¼úÈÄ °¨¿° ¶Ç´Â ÃâÇ÷ µî¿¡ ´ëÇÑ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù.
¿µ¹® target tissue ÇÑ±Û Ç¥ÀûÁ¶Á÷
¼³¸í   
  È£¸£¸ó¿¡ ´ëÇÏ¿© Ç¥ÀûÀÌ µÇ´Â ¼¼Æ÷¶ó´Â Àǹ̷μ­ ±× È£¸£¸ó¿¡ ´ëÇÑ ¼ö¿ëü¸¦ °¡Áö°í Àִ ¼¼Æ÷. ¿¹¸¦ µé¾î Àν¶¸°Àº Àν¶¸° ¼ö¿ëü¸¦ °¡Áø ¼¼Æ÷¸¦ Ç¥Àû¼¼Æ÷·Î ÇÏ¿© ÀÌ ¼¼Æ÷¿¡¸¸ ÀÛ¿ëÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • effective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½¼öÁØ, ½ÇÁ¦°¨°¢¼ÒÀ½¼öÁØ
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse drug reaction
    ¾à¹°À¯ÇعÝÀÀ
  • adverse effect
    À¯ÇØÈ¿°ú
  • adverse reaction
    À¯ÇعÝÀÀ
  • accommodative target
    Á¶ÀýÀ¯¹ß½ÃÇ¥
  • source-target distance
    ¿øÃµÇ¥Àû»çÀ̰Ÿ®, ¿øÃµÇ¥Àû°£°Å¸®
  • target
    1. Ç¥Àû 2. Ç¥Àû¼¼Æ÷
  • target cell
    Ç¥Àû¼¼Æ÷
  • target cell anemia
    Ç¥Àû¼¼Æ÷ºóÇ÷
  • target configuration
    °ú³á¸ð¾ç, Ç¥Àû¸ð¾ç
  • target gland
    Ç¥Àû»ù, Ç¥Àû¼±
  • target lesion
    Ç¥Àûº´ÅÍ
  • target organ
    Ç¥ÀûÀå±â
  • target population
    Ç¥ÀûÁý´Ü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • diphteria and tetanus toxoids and acellular pert vaccine
    °³·®µðÇÇÆ¼
  • target cell
    Ç¥Àû¼¼Æ÷
  • discrimination
    ½Äº°, ÆÇº°, ºÐº°
  • speech discrimination
    ¾îÀ½¸í·áµµ, ¸»¼Ò¸®¸í·áµµ
  • target organ
    Ç¥ÀûÀå±â
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse effect
    (¢¡ adverse event) À¯ÇذæÇè
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • kidney ureter and bladder
    ÄáÆÏ¿ä°ü¹æ±¤´Ü¼øÃÔ¿µ
  • dilatation and curettage
    Àڱñܾ¼ú, ÀÚ±Ã¼ÒÆÄ¼ú
  • peritoneal oocyte and sperm transfer
    »ý½Ä¼¼Æ÷º¹°­³»À̽Ä, »ý½Ä¼¼Æ÷º¹°­³»Àü´Þ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • delusion of persecution
    ÇÇÇØ¸Á»ó
  • effective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½¼öÁØ, ½ÇÁ¦°¨°¢¼ÒÀ½
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse reaction
    ºÎÀÛ¿ë
  • adverse selection
    ¿ª¼±ÅÃ
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • accommodative target
    Á¶ÀýÀ¯¹ß½ÃÇ¥
  • target cell anemia
    Ç¥ÀûÀûÇ÷±¸ºóÇ÷
  • clinical target volume
    ÀÓ»óÇ¥ÀûüÀû
  • target cell
    Ç¥Àû¼¼Æ÷
  • target configuration
    °ú³á¸ð¾ç, Ç¥Àû¸ð¾ç
  • source-target distance
    ¼±¿øÇ¥Àû°£°Å¸®
  • target skin distance
    Ç¥ÀûÇǺΰŸ®
  • target gland
    Ç¥Àû»ù
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • pitch discrimination
    À½Á¶½Äº°.
  • EPNDB =effective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½·¹º§, ½ÇÁ¦°¨°¢¼ÒÀ½
  • EPNDB=ÊÝeffective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½·¹º§.
  • hoof and mouth disease =foot and mouth d.
    ±¸Á¦(¿ª)(Ï¢ð´æ¹) º´.
  • accommodative target
    Á¶ÀýÀ¯¹ß½ÃÇ¥
  • fusional target
    À¶ÇÕÇ¥Áö
  • planning target volume
    °èȹ¿ë Ç¥ÀûºÎÇÇ
  • radiation,target theory of
    ¡­ÀÇ Ç¥ÀûÀÌ·Ð(¡­øöîÜìµÖå)
  • ADR : adverse drug reaction
    ¾à¹°À¯ÇØÀÛ¿ë(å·ÚªêóúªíÂéÄ).
  • adverse action
    À¯ÇØ(êóúª)ÀÛ¿ë.
  • adverse effect
    ¿ªÈ¿°ú(æ½üùÍý).¾à¸®À¯ÇØÈ¿°ú.
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse event
    À¯ÇØ»ç·Ê(êóúªÞÀçÓ).
  • adverse reaction
    À¯ÇØ(êóúª)¹ÝÀÀ, ¿ª(æ½)¹ÝÀÀ.
  • adverse reaction
    ºÎÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • effective perceived noise level =EPNDB
    ½ÇÈ¿°¨¼ö¼ÒÀ½(Ëà̷˧ËÛËÛËô)·¹ º§.
  • adverse action
    À¯ÇØ(êóúª)ÀÛ¿ë.
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse effect
    ¿ªÈ¿°ú(æ½üùÍý).¾à¸®À¯ÇØÈ¿°ú.
  • adverse event
    À¯ÇØ»ç·Ê(êóúªÞÀçÓ).
  • adverse reaction
    ºÎÀÛ¿ë
  • adverse reaction
    À¯ÇØ(êóúª)¹ÝÀÀ, ¿ª(æ½)¹ÝÀÀ.
  • adverse reactions
    ºÎÀÛ¿ë
  • adverse selection
    ¿ª¼±ÅÃ.
  • drug reactions, adverse
    ¾à¹°¹ÝÀÀ(¡­Úãëë), ºÎÀÛ¿ë(ÜùíÂéÄ)
  • untoward effect =adverse reaction, unwanted reaction
    À¯ÇعÝÀÀ(êóúªÚãëë), ºÎÀÛ¿ë
  • untoward effect =adverse reaction, unwanted reaction
    À¯ÇعÝÀÀ(êóúªÚãëë), ¾àÇØ(å·úª)¹ÝÀÀ.[¾à¸®]ºÎÀÛ¿ë, ºÒ¿øÀÛ¿ë.
  • hoof and mouth disease =foot and mouth d.
    ±¸Á¦(¿ª)(Ï¢ð´æ¹) º´.
  • papilomatosis of Gougerot and Carteaud => confluent and reticulated pa
  • color discrimination
    »öäºÐº°(ßäóôÝÂܬ)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Tendon sheath of abductor longus and extenor brevis
    ±ä¾öÁö¹ú¸²±Ù°úªÀº¾öÁöÆï±ÙÈûÁÙÁý
    [¿¾ ¿ë¾î] À幫Áö¿ÜÀü±Ù ¹× ´Ü¹«Áö½Å±Ù°ÇÃÊ
  • Lymph nodes of head and neck
    ¸Ó¸® ¹× ¸ñ¸²ÇÁÀý
    [¿¾ ¿ë¾î] µÎ°æºÎÀÓÆÄÀý
  • White matter (Tracts and Fascicles)
    ¹é»öÁú(½Å°æ·Î¿Í ½Å°æ´Ù¹ß)
    [¿¾ ¿ë¾î] ¹éÁú
  • Fold and fossa
    º¹¸·ÁÖ¸§°ú º¹¸·¿À¸ñ
    [¿¾ ¿ë¾î] º¹¸·ÁÖ¸§°ú º¹¸·¿Í
  • Tendon sheath of extensor digitorum and extensor indicis
    ¼Õ°¡¶ôÆï±Ù°úÁý°ÔÆï±ÙÈûÁÙÁý
    [¿¾ ¿ë¾î] Áö½Å±Ù ¹× ½ÃÁö½Å±Ù°ÇÃÊ
  • Sections of thalamus and metathalamus
    ½Ã»ó ¹× ½Ã»óÈĺÎÀÇ ´Ü¸é
    [¿¾ ¿ë¾î] ½Ã»ó ¹× ½Ã»óÈĺÎÀÇ ´Ü¸é
  • Tracts and fascicles of thalamus
    ½Ã»óÀÇ ½Å°æ·Î ¹× ½Å°æ´Ù¹ß
    [¿¾ ¿ë¾î] ½Ã»ó·Î ¹× ½Ã»ó¼Ó
  • Tracts and fascicles of hypothalamus
    ½Ã»óÇϺÎÀÇ ½Å°æ·Î ¹× ½Å°æ´Ù¹ß
    [¿¾ ¿ë¾î] ½Ã»óÇϺηΠ¹× ½Ã»óÇϺμÓ
  • Period of mature neural groove and immature somite
    ½Å°æ°í¶û¼º¼÷ ¹× ¸öºÐÀý¹Ì¼º¼÷±â
    [¿¾ ¿ë¾î] ½Å°æ±¸Çü¼ºÈÄ±â ¹× Ã¼ÀýÇü¼ºÀü±â
  • Medial and inferior surface
    ¾ÈÂÊ¸é ¹× ¾Æ·¡¸é
    [¿¾ ¿ë¾î] ³»Ãø¸é°ú Çϸé
  • Sacral nerves and coccygeal nerve
    ¾ûÄ¡½Å°æ ¹× ²¿¸®½Å°æ
    [¿¾ ¿ë¾î] õ°ñ½Å°æ ¹× ¹Ì°ñ½Å°æ
  • Lobar and segmental bronchi
    ¿±±â°üÁö¿Í ±¸¿ª±â°üÁö
    [¿¾ ¿ë¾î] ¿±±â°üÁö¿Í ±¸±â°üÁö
  • Muscles of palate and fauces
    ÀÔõÀå ¹× ¸ñ±¸¸Û±ÙÀ°
    [¿¾ ¿ë¾î] ±¸°³ ¹× ±¸Çù±Ù
  • Muscles of palate and fauces
    ÀÔõÀå ¹× ¸ñ±¸¸Û±ÙÀ°
    [¿¾ ¿ë¾î] ±¸°³±Ù ¹× ±¸Çù±Ù
  • Mode and course of progress
    ÁøÇà¾ç½Ä ¹× °úÁ¤
    [¿¾ ¿ë¾î] ÁøÇà¾ç½Ä¹×°úÁ¤
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • target cell
    Ç¥Àû¼¼Æ÷ (øöîÜá¬øà)
  • target molecular weight
    Ç¥ÀûºÐÀÚ·® (øöîÜÝÂí­Õá)
  • target organ
    Ç¥Àû±â°ü (øöîÜÐïί)
  • target sequence
    Ç¥Àû¼­¿­ (øöîÜßíÖª)
  • target theory
    Ç¥ÀûÀÌ·Ð (øöîÜ×âÖå)
  • ball and stick model
    °ø ¸·´ë ¸ðµ¨
  • breakage and reunion model
    Àý´ÜÀç°áÇÕ(ï·Ó¨î¢Ì¿ùê)¸ðµ¨
  • cut and patch repair
    Àß¶ó±é±â ¼öº¹(áóÜÖ) (ÔÒ) excision repair
  • Dean and Webb method
    µò°ú¿þºê ¹ý(Ûö)
  • Jacob and Monod hypothesis
    Àð°ö¡¤¸ð³ë ¼³(àã)
  • knife and fork model
    ³ªÀÌÇÁÆ÷Å© ¸ðµ¨
  • "Koshland, Nemethy, and Filmer model"
    "ÄÚ½¬·»µå,³×¸ÞƼ,ÇÊ¸Ó ¸ðµ¨"
  • Lavoisier and Laplace law
    ¶óº¸¾ÆÁ¦ ¶óÇÁ¶óÀ̽º¹ýÄ¢(ÛööÎ)
  • lock and key theory
    ÀÚ¹°¼è-¿­¼èÀÌ·Ð(ìµÖå)
  • modification and restriction
    ¼ö½Ä(áóãÞ)°ú Á¦ÇÑ(ð¤ùÚ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • discrimination
    ½ÄÆÇº°
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse reaction
    ºÎÀÛ¿ë, À¯ÇعÝÀÀ, À¯ÇØÀÛ¿ë, ¿ª¹ÝÀÀ
  • target
    Ç¥Àû, °ú³á
  • target configuration
    °ú³á¸ð¾ç, Ç¥Àû¸ð¾ç
  • target organ
    Ç¥Àû±â°ü
  • target pattern
    °ú³á¾ç»ó
  • target sign
    °ú³á¡ÈÄ
  • ball and socket joint
    Àý±¸°øÀ̰üÀý
  • ENT [=ear, nose and throat]
    À̺ñÀÎÈİúÇÐ
  • growth and development
    ¼ºÀå°ú ¹ßÀ°
  • infant and child
    ¿µÀ¯¾Æ, À¯¼Ò¾Æ
  • intake and output
    ¼·Ãë¿Í ¹è¼³
  • kidney ureter and bladder [=KUB]
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PN papillary necrosis; parenteral nutrition; penicillin; perceived noise; percussion note; periarteriti...
LEPN effective perceived noise level
PNdb perceived noise decibel
PQOL Perceived Quality of Life [scale]
RPE rate of perceived exertion; recurrent pulmonary embolism; retinal pigment epithelium; ribulose 5-pho...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DD Drug discrimination
PSS Perceived Stress Scale
PD Power of Discrimination
RPE Rate of perceived exertion
RPE Rating of Perceived Exertion
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • Z60.5
    Target of perceived adverse discrimination and persecution
    À¯ÇØÇÑ Â÷º° ¹× ¹ÚÇØ¸¦ ¹Þ´Â ¸ñÇ¥¹°
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • perceived color
    ÀÎÁö»ö
  • perceived sensation
    ÀÎÁö °¨°¢
  • discrimination
    ½Äº°
  • maximum discrimination score
    ÃÖ´ë ¸í·áÄ¡
  • tonal discrimination
    À½»ö ½Äº°, À½Á¶ ½Äº°, À½ ½Äº°
  • two-point discrimination testing
    µÎ Á¡ ½Äº°´É °Ë»ç
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse drug reaction
    ¾à¹°ÀÇ ºÎÀÛ¿ë
  • adverse event
    À¯ÇØ »ç·Ê
  • adverse loading
    À¯ÇØ ÇÏÁß, ÇØ·Î¿î ÇÏÁß
  • adverse selection
    ¿ª ¼±ÅÃ
  • systemic adverse effect
    Àü½Å¼º ºÎÀÛ¿ë
  • mean target dose
    Æò±Õ Ç¥Àû ¼±·®
  • projection target
    Åõ»ç Ç¥Àû
  • target
    ´ë»ó, Ç¥Àû, ¸ñÇ¥¹°
    1. ¾î¶² °ÍÀÌ ÇâÇÏ´Â ¸ñÀû¹° ¶Ç´Â Àå¼Ò. ¿¹ÄÁ´ë ¿¢½º¼± °ü¿¡ À־, ÀüÀÚ°¡ Ãæµ¹µÇ¾î ¿¢½º¼±À» ¹ßÇÏ´Â ±Ý¼Ó ¶Ç´Â ÆÇ°ú °°Àº °Í. 2. ¾î¶² Ư¼ö ¹°Áú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
persecution complex A feeling that others have evil designs against one's well-being.
(05 Mar 2000)
delusion of persecution A false notion that one is being persecuted, characteristic symptom of paranoid schizophrenia.
(27 Sep 1997)
pitch discrimination The ability to differentiate tones.
(12 Dec 1998)
speech discrimination tests Tests of the ability to hear and understand speech as determined by scoring the number of words in a word list repeated correctly.
(12 Dec 1998)
discrimination <psychology> Differential response to different stimuli.
(12 Dec 1998)
discrimination learning Learning that is manifested in the ability to respond differentially to various stimuli.
(12 Dec 1998)
adverse Harmful.
(18 Nov 1997)
adverse drug reaction reporting systems Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
(12 Dec 1998)
adverse effect This is an abnormal or harmful effect to an organism caused by exposure to a chemical. It is indicated by some result such as death, a change in food or water consumption, altered body and organ weights, altered enzyme levels, or visible illness. An effect may be classed as adverse if it causes functional or anatomical damage, causes irreversible change in the homeostasis of the organism, or increases the susceptibility of the organism to other chemical or biological stress. A non-adverse effect will usually be reversed when the organism is no longer being exposed to the chemical.
(09 Oct 1997)
adverse event A toxic reaction to a medical therapy.
(09 Oct 1997)
adverse reaction Any undesirable or unwanted consequence of a preventive, diagnostic, or therapeutic procedure or regimen.
(05 Mar 2000)
no-observed-adverse-effect level The highest dosage administered that does not produce toxic effects. The noael will depend on how closely dosages are spaced (lowest-observed-adverse-effect level and no-observed-effect level) and the number of animals examined. The ultimate objective is usually to determine not the "safe" dosage in laboratory animals but the "safe" dosage for humans. Therefore, the extrapolation most often required of toxicologists is from high-dosage studies in laboratory animals to low doses in humans. (casarett and doull's toxicology: the basic science of poisons, 4th ed)
(12 Dec 1998)
event, adverse In pharmacology, an adverse event is any unexpected or dangerous reaction to a drug.
(12 Dec 1998)
GI-tract target lesion <radiology> Metastatic melanoma, primary neoplasm, spindle cell tumour (benign or malignant), lymphoma, carcinoid, carcinoma, metastasis, breast carcinoma, lung carcinoma, renal carcinoma, Kaposi's sarcoma, eosinophilic granuloma, ectopic pancreas
(12 Dec 1998)
molybdenum target tube An X-ray tube with an anode surface made of molybdenum instead of tungsten, used in mammography.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • perceived noise decibel
    °¨°¢ ¼ÒÀ½ µ¥½Ãº§
  • adverse
    ¿ªÀÇ, ºÒ¿îÇÑ, ¹Ý´ëÇÏ´Â
  • adverse
    ¿ªÀÇ;°Å²Ù·ÎÀÇ;¹Ý´ëÀÇ;ÀûÀǰ¡ ÀÖ´Â;ºÒ¸®ÇÑ
  • persecution
    Á¾±³Àû ¹ÚÇØ
  • persecution complex(mania)
    ÇÇÇØ(¹ÚÇØ)¸Á»ó
  • target
    Ç¥Àû
  • target
    °ú³á;¸ñÇ¥;¸ñÇ¥¾×;hit a ~ °ú³á¿¡ ¸ÂÈ÷´Ù;¸ñÇ¥¾×¿¡ ´ÞÇÏ´Ù
  • target practice
    »ç°Ý¿¬½À
  • discrimination
    ±¸º°
  • discrimination
    ±¸º°;Â÷º°;½Äº°
  • price discrimination
    °¡°Ý Â÷º°(°°Àº »óǰÀ» »ó´ë¿¡ µû¶ó ´Ù¸¥ °ª¿¡ ÆÈ±â)
  • reverse discrimination
    ¿ªÂ÷º°(ÇÇÂ÷º°ÀÚ ¿ì´ë·Î »ý±â´Â ±×¹ÛÀÇ »ç¶÷ÀÇ ºÒ¸®)
  • again and again
    ¹Ýº¹Çؼ­
  • and
    ±×¸®°í
  • and not ~ either
    ¶Ç ~ ¾Æ´Ï´Ù(=nor)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á